Show simple item record

dc.contributor.authorGarofalo, M.
dc.contributor.authorSaari, H.
dc.contributor.authorSomersalo, P.
dc.contributor.authorCrescenti, D.
dc.contributor.authorKuryk, L.
dc.contributor.authorAksela, L.
dc.contributor.authorCapasso, C.
dc.contributor.authorMadetoja, M.
dc.contributor.authorKoskinen, Katariina
dc.contributor.authorOksanen, T.
dc.contributor.authorMäkitie, A.
dc.contributor.authorJalasvuori, Matti
dc.contributor.authorCerullo, V.
dc.contributor.authorCiana, P.
dc.contributor.authorYliperttula, M.
dc.date.accessioned2018-07-03T07:08:32Z
dc.date.available2018-07-03T07:08:32Z
dc.date.issued2018
dc.identifier.citationGarofalo, M., Saari, H., Somersalo, P., Crescenti, D., Kuryk, L., Aksela, L., Capasso, C., Madetoja, M., Koskinen, K., Oksanen, T., Mäkitie, A., Jalasvuori, M., Cerullo, V., Ciana, P., & Yliperttula, M. (2018). Antitumor effect of oncolytic virus and paclitaxel encapsulated in extracellular vesicles for lung cancer treatment. <i>Journal of Controlled Release</i>, <i>283</i>, 223-234. <a href="https://doi.org/10.1016/j.jconrel.2018.05.015" target="_blank">https://doi.org/10.1016/j.jconrel.2018.05.015</a>
dc.identifier.otherCONVID_28085017
dc.identifier.otherTUTKAID_77809
dc.identifier.urihttps://jyx.jyu.fi/handle/123456789/58820
dc.description.abstractStandard of care for cancer is commonly a combination of surgery with radiotherapy or chemoradiotherapy. However, in some advanced cancer patients this approach might still remaininefficient and may cause many side effects, including severe complications and even death. Oncolytic viruses exhibit different anti-cancer mechanisms compared with conventional therapies, allowing the possibility for improved effect in cancer therapy. Chemotherapeutics combined with oncolytic viruses exhibit stronger cytotoxic responses and oncolysis. Here, we have investigated the systemic delivery of the oncolytic adenovirus and paclitaxel encapsulated in extracellular vesicles (EV) formulation that, in vitro, significantly increased the transduction ratio and the infectious titer when compared with the virus and paclitaxel alone. We demonstrated that the obtained EV formulation reduced the in vivo tumor growth in animal xenograft model of human lung cancer. Indeed, we found that combined treatment of oncolytic adenovirus and paclitaxel encapsulated in EV has enhanced anticancer effects both in vitro and in vivo in lung cancer models. Transcriptomic comparison carried out on the explanted xenografts from the different treatment groups revealed that only 5.3% of the differentially expressed genes were overlapping indicating that a de novo genetic program is triggered by the presence of the encapsulated paclitaxel: this novel genetic program might be responsible of the observed enhanced antitumor effect. Our work provides a promising approach combining anticancer drugs and viral therapies by intravenous EV delivery as a strategy for the lung cancer treatment.fi
dc.format.mimetypeapplication/pdf
dc.language.isoeng
dc.publisherElsevier BV
dc.relation.ispartofseriesJournal of Controlled Release
dc.rightsCC BY 4.0
dc.subject.othercancer therapy
dc.subject.otherdrug delivery
dc.subject.otherpaclitaxel
dc.subject.otherxenograft animal model
dc.subject.otherlung cancer
dc.titleAntitumor effect of oncolytic virus and paclitaxel encapsulated in extracellular vesicles for lung cancer treatment
dc.typearticle
dc.identifier.urnURN:NBN:fi:jyu-201806253343
dc.contributor.laitosBio- ja ympäristötieteiden laitosfi
dc.contributor.laitosDepartment of Biological and Environmental Scienceen
dc.contributor.oppiaineSolu- ja molekyylibiologiafi
dc.contributor.oppiaineNanoscience Centerfi
dc.contributor.oppiaineCell and Molecular Biologyen
dc.contributor.oppiaineNanoscience Centeren
dc.type.urihttp://purl.org/eprint/type/JournalArticle
dc.date.updated2018-06-25T09:15:20Z
dc.description.reviewstatuspeerReviewed
dc.format.pagerange223-234
dc.relation.issn0168-3659
dc.relation.numberinseries0
dc.relation.volume283
dc.type.versionpublishedVersion
dc.rights.copyright© 2018 The Authors. Published by Elsevier B.V.
dc.rights.accesslevelopenAccessfi
dc.subject.ysoviroterapia
dc.subject.ysoonkolyyttinen virushoito
dc.subject.ysoonkolyyttiset virukset
dc.subject.ysosyöpähoidot
dc.subject.ysokeuhkosyöpä
dc.subject.ysosolunulkoiset vesikkelit
dc.format.contentfulltext
jyx.subject.urihttp://www.yso.fi/onto/yso/p21936
jyx.subject.urihttp://www.yso.fi/onto/yso/p28561
jyx.subject.urihttp://www.yso.fi/onto/yso/p28562
jyx.subject.urihttp://www.yso.fi/onto/yso/p27422
jyx.subject.urihttp://www.yso.fi/onto/yso/p19573
jyx.subject.urihttp://www.yso.fi/onto/yso/p38903
dc.rights.urlhttps://creativecommons.org/licenses/by/4.0/
dc.relation.doi10.1016/j.jconrel.2018.05.015


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

CC BY 4.0
Except where otherwise noted, this item's license is described as CC BY 4.0